Heat Biologics Price Target Raised to $18.00 at Cantor Fitzgerald (HTBX)
Cantor Fitzgerald hoisted their price objective on shares of Heat Biologics (NASDAQ:HTBX) from $15.00 to $18.00 in a research note issued on Wednesday, ARN reports. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 23.29% from the stock’s previous close.
Separately, analysts at Aegis initiated coverage on shares of Heat Biologics (NASDAQ:HTBX) in a research note to investors on Wednesday, September 18th. They set a “buy” rating and a $36.00 price target on the stock.
Heat Biologics (NASDAQ:HTBX) traded up 15.87% during mid-day trading on Wednesday, hitting $14.60. The stock had a trading volume of 186,687 shares. Heat Biologics has a 1-year low of $9.01 and a 1-year high of $13.50. The stock has a 50-day moving average of $10. and a 200-day moving average of $10.57. The company’s market cap is $90.4 million.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.